These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

954 related articles for article (PubMed ID: 28578693)

  • 41. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest.
    Francis AM; Alexander A; Liu Y; Vijayaraghavan S; Low KH; Yang D; Bui T; Somaiah N; Ravi V; Keyomarsi K; Hunt KK
    Mol Cancer Ther; 2017 Sep; 16(9):1751-1764. PubMed ID: 28619757
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
    Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
    [No Abstract]   [Full Text] [Related]  

  • 43. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
    Cao Y; Li X; Kong S; Shang S; Qi Y
    J Cell Mol Med; 2020 May; 24(9):5135-5145. PubMed ID: 32277580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of sinomenine hydrochloride on radiosensitivity of esophageal squamous cell carcinoma cells.
    Fu S; Jin L; Gong T; Pan S; Zheng S; Zhang X; Yang T; Sun Y; Wang Y; Guo J; Hui B; Zhang X
    Oncol Rep; 2018 Apr; 39(4):1601-1608. PubMed ID: 29393484
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Novel Methoxybenzyl 5-Nitroacridone Derivative Effectively Triggers G1 Cell Cycle Arrest in Chronic Myelogenous Leukemia K562 Cells by Inhibiting CDK4/6-Mediated Phosphorylation of Rb.
    Zhang B; Zhang T; Zhang TY; Wang N; He S; Wu B; Jin HX
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
    Witkiewicz AK; Borja NA; Franco J; Brody JR; Yeo CJ; Mansour J; Choti MA; McCue P; Knudsen ES
    Oncotarget; 2015 Jun; 6(18):15788-801. PubMed ID: 26158861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plumbagin, a natural naphthoquinone, inhibits the growth of esophageal squamous cell carcinoma cells through inactivation of STAT3.
    Cao Y; Yin X; Jia Y; Liu B; Wu S; Shang M
    Int J Mol Med; 2018 Sep; 42(3):1569-1576. PubMed ID: 29901084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
    Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
    Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Baicalein induces G1 arrest in oral cancer cells by enhancing the degradation of cyclin D1 and activating AhR to decrease Rb phosphorylation.
    Cheng YH; Li LA; Lin P; Cheng LC; Hung CH; Chang NW; Lin C
    Toxicol Appl Pharmacol; 2012 Sep; 263(3):360-7. PubMed ID: 22820424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
    Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
    Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo.
    Liu L; Hou L; Gu S; Zuo X; Meng D; Luo M; Zhang X; Huang S; Zhao X
    Oncol Rep; 2015 Jan; 33(1):297-303. PubMed ID: 25333353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in
    Shi R; Li M; Raghavan V; Tam S; Cabanero M; Pham NA; Shepherd FA; Moghal N; Tsao MS
    Clin Cancer Res; 2018 Dec; 24(23):5990-6000. PubMed ID: 30093452
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The anticancer activity of the substituted pyridone-annelated isoindigo (5'-Cl) involves G0/G1 cell cycle arrest and inactivation of CDKs in the promyelocytic leukemia cell line HL-60.
    Saleh AM; Aljada A; El-Abadelah MM; Taha MO; Sabri SS; Zahra JA; Aziz MA
    Cell Physiol Biochem; 2015; 35(5):1943-57. PubMed ID: 25870953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual
    Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
    Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
    [No Abstract]   [Full Text] [Related]  

  • 59. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
    Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
    Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.